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Summary
Objective: Recent studies revealed a close connection between adipose tissue, adipokines and articular degenerative inﬂammatory diseases
such as rheumatoid arthritis (RA) and osteoarthritis (OA). The goal of this work was to investigate the activity of adiponectin in human and
murine chondrocytes and to study its functional role in the modulation of nitric oxide synthase type II (NOS2). For completeness, interleukin
(IL)-6, IL-1b, matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, prostaglandin E2 (PGE2), leu-
kotriene B4 (LTB4), tumor necrosis factor alpha (TNF)-a and monocyte chemoattractant protein-1 (MCP-1) accumulation have been evaluated
in adiponectin-stimulated chondrocytes cell culture supernatants.
Methods: Murine ATDC5 cell line, C28/I2, C20A4, TC28a2 human immortalized chondrocytes, and human cultured chondrocytes were used.
Nitrite accumulation was determined by Griess reaction. Adiponectin receptors (AdipoRs) expression was evaluated by immunoﬂuorescence
microscopy and conﬁrmed by reverse transcriptase-polymerase chain reaction. NOS2 expression was evaluated by Western blot analysis
whereas cytokines, prostanoids and metalloproteinases production was evaluated by speciﬁc enzyme-linked immunosorbent assays.
Results: Human and murine chondrocytes express functional AdipoRs. Adiponectin induces NOS2. This effect is inhibited by aminoguanidine,
dexamethasone and by a selective inhibitor of phosphatidylinositol 3-kinase. In addition, adiponectin is able to increase IL-6, MMP-3, MMP-9
and MCP-1 by murine cultured chondrocytes whereas it was unable to modulate TNF-a, IL-1b, MMP-2, TIMP-1, PGE2 and LTB4 release.
Conclusions: These results bind more closely the interactions between fat-derived adipokines and articular inﬂammatory diseases, and
suggest that adiponectin is a novel key element in the maintenance of cartilage homeostasis which might be considered as a potential
therapeutical target in joint degenerative diseases.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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1101Introduction
The concept of white adipose tissue (WAT) as a passive
tissue in charge of maintaining only whole body energy
reserve has been radically modiﬁed after the discovery of
leptin and it’s wide ranging physiological activity in 19941.
So, WAT is emerging as a dynamic sharer in the regulation
of physiopathological processes including immunity and
inﬂammation and it is no longer viewed as a simply storage
depot for body energy2.
WAT has been described to produce and secrete a pleth-
ora of peptides that participates in diverse metabolic pro-
cesses via endocrine, paracrine, autocrine and juxtacrine
models of action. In addition, some of these factors have
been acknowledged as pro-inﬂammatory mediators with
cytokine-like activity, now called adipokines3. The grade
of present knowledge is that adipose tissue is a critical
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sues and organs including adrenal, central and peripheral
nervous system, and immune system.
Thus, WAT is now considered as a source of pro-
inﬂammatory peptides that signiﬁcantly contributes to the
so-called ‘‘low grade inﬂammatory state’’ noted particu-
larly in subjects with obesity and metabolic syndrome4.
This cluster of metabolic abnormalities is characterized
by insulin resistance, dyslipidemia, alteration of coagula-
tion, and it is associated with increased risk of cancer,
type II diabetes, cardiovascular complications and autoim-
mune inﬂammatory diseases. It is dutiful to underline that
WAT also produces, likely as an adaptive response, anti-
inﬂammatory factors such as interleukin (IL)-1 receptor
antagonist (IL1-RA) and IL-10, circulating levels of both
are also elevated in obese individuals5.
The basis for obesity as pro-inﬂammatory state is that
several markers of inﬂammation, including pro-inﬂammatory
cytokines and acute phase proteins, are elevated in obese
subjects6. Apparently simple, the physiology of adipocytes
has been ignored along decades, but several evidences re-
vealed to be extremely complex and ﬁnely tuned. Following
the seminal discovery of leptin, many research efforts have
been devoted to the identiﬁcation of other proteic factors
speciﬁcally secreted by adipocytes, and, in the last 10 years
more than 50 factors have been characterized and consti-
tuted the so-called ‘‘adipokinome’’.
Therefore, it is of particular interest that recent studies
have revealed multiple links among adipose tissue, adipo-
kines, and inﬂammatory joint diseases. For instance, pro-in-
ﬂammatory cytokines have been described to be produced
by the infrapatellar fat pad of osteoarthritic subjects7. More-
over, studies aimed to determine adipokine levels in inﬂam-
matory articular diseases have demonstrated high levels of
adiponectin and resistin in the synovial ﬂuid of patients with
osteoarthritis (OA) and rheumatoid arthritis (RA)8.
Adiponectin, also called GBP-28, apM1, Acrp 30 or Adi-
poQ, is a 244 aa adipose tissue speciﬁc protein that has
structural homology to collagen VIII and X and complement
factor C1q9,10. Thus, it belongs to the C1q-tumor necrosis
factor (TNF) super-family, whose members are thought to
be derived from a common ancestral molecule and to share
common ‘‘pro-inﬂammatory’’ properties11. Adiponectin cir-
culates in the blood in large amounts and constitutes about
0.01% of total plasma proteins. Adiponectin is present in
serum as oligomeric isoforms constituted prevalently by tri-
mers, hexamers but also by high molecular weight isoforms
(12e18 mer)12.
Adiponectin has been investigated primarily in the context
of energetic substrate metabolism (fatty acids and glu-
cose)13 and for its role on the cardiovascular system,
wherein it has been suggested to act as anti-atherosclerotic
factor and to exert, in general, anti-inﬂammatory properties
at the endothelial level14,15. At cartilage level, Chen et al.
suggested that adiponectin is involved in the modulation of
cartilage destruction in chondrocytes by up-regulating
tissue inhibitor of metalloproteinase (TIMP)-2 and down-reg-
ulating IL-1b-induced matrix metalloproteinase (MMP)-1316.
In contrast, our ﬁndings of elevated adiponectin levels in
RA patients17, conﬁrmed also by other authors8, which
demonstrated elevated adiponectin levels in synovial ﬂuid
of RA patients suggested a pro-inﬂammatory role for this
adipokine. In addition, recent reports, demonstrated that
adiponectin is expressed in synovial ﬁbroblasts18, and that
adiponectin enhances IL-6 production via a complex path-
way involving speciﬁc adiponectin receptors (AdipoRs)
and intracellular intermediates18,19.Given the fact that other members of the C1q-TNF super-
family are involved in articular degenerative diseases path-
ophysiology, and considering that other adipokines, such as
leptin, have been described to act as pro-inﬂammatory
factor at joint level20e22, it was conceivable to hypothesize
that other adipokines, and particularly adiponectin, might
play a distinct pathogenic role in inﬂammatory joint diseases
by acting at the unique cellular component of articular
cartilage: the chondrocyte.
Therefore, in this study we investigated the functional role
of adiponectin as modulator of inﬂammatory response by
using as molecular target the nitric oxide synthase type II
(NOS2). In addition, other relevant factors involved in the
inﬂammatory response in chondrocytes upon adiponectin
stimulation have been evaluated.MethodsREAGENTSAll culture reagents were purchased from SIGMA (St Louis, MO, USA),
except Dulbecco’s modiﬁed Eagle’s medium (DMEM)/Ham’s F12 medium
and Trypsineethylenediaminetetraacetic acid (EDTA) that was from Lonza
(Lonza Group Ltd, Basel, Switzerland). Reverse transcriptase-polymerase
chain reaction (RT-PCR) products were supplied by Invitrogen (Life Technol-
ogies, Carlsbad, CA, USA) and Stratagene (Cedar Creeck, TX, USA) and
full-length adiponectin by Biocat (BioVision Research Products, Mountain
View, CA, USA).CELL CULTURE AND TREATMENTSThe clonal chondrogenic cell line ATDC5 was chosen for these studies
because it has been shown to be a useful in vitro model for examining the
multistep differentiation of chondrocytes. Undifferentiated ATDC5 cells prolif-
erate rapidly until they reach conﬂuence, at which point they undergo growth
arrest. When treated with insulin, transferrin and sodium selenite, conﬂuent
ATDC5 cells re-enter a proliferative phase and form cartilaginous matrix
nodules (mature chondrocytes). As differentiation progresses, these cells
undergo a late differentiation phase, becoming hypertrophic, calcifying chon-
drocytes that synthesize type X collagen and osteopontin e a marker of
terminal chondrocyte differentiation23. ATDC5 cells were a kind gift from
Dr Agamemnon E Grigoriadis (Department of Craniofacial Development,
King’s College, London Guy’s Hospital, London, UK). Unless otherwise
speciﬁed, cells were cultured in DMEM/Ham’s F12 medium supplemented
with 5% fetal bovine serum (FBS), 10 mg/ml human transferrin, 3
108 mol/l sodium selenite and antibiotics (50 U/ml penicillin and 50 mg/ml
streptomycin). ATDC5 cells were used in both undifferentiated and differen-
tiated stage as they have shown a similar behavior in all differentiation
stages, at least in term of nitric oxide (NO) type II activation20. The immortal-
ized human juvenile costal chondrocytes cell lines TC28a2, C20/A4, and
C28/I2 were cultured in DMEM/F12 as described previously24 supplemented
with 10% FBS, L-glutamine, and antibiotics. Human normal articular cartilage
samples (a kind gift of Mary B. Goldring, Hospital for Special Surgery, NYC,
USA) were obtained from knee joints of patients undergoing leg amputations
from above the knee because of peripheral vascular disease. (Permission
from the local ethical committee was granted.) None of the patients had
a clinical history of arthritis or any other pathology affecting the cartilage,
and the specimens appeared normal on morphological examination (no
change in color and no ﬁbrillation). Articular osteoarthritic cartilage samples
were obtained from femoral condyles of patients with clinical history of OA
undergoing leg amputations as above described. Samples were taken
from the main defective area of maximal load. Patients with RA (or other au-
toimmune disease), infection-induced OA and posttraumatic OA have not
been considered for cartilage sample harvesting. For chondrocyte isolation,
aseptically dissected cartilage was subjected to sequential digestion with
pronase (catalog number 165921; Roche Molecular Biochemicals, Indianap-
olis, IN, USA) and collagenase P (catalog number 1213873; Roche Molecu-
lar Biochemicals) at a ﬁnal concentration of 1 mg/ml in DMEM/F12 plus 10%
FBS and sterilized by ﬁltration, in accordance with the manufacturer’s in-
structions. Cartilage specimens were ﬁnely diced in phosphate-buffered sa-
line (PBS), and after removing PBS diced tissue was incubated for 30 min
with pronase in a shaking water bath at 37C. Pronase was subsequently re-
moved from the digestion ﬂask and the cartilage pieces were washed with
PBS. After removal of PBS, digestion was continued with addition of collage-
nase P; this was done over 6e8 h in a shaking water bath at 37C. The re-
sulting cell suspension was ﬁltered through a 40-mm nylon cell strainer (BD
Biosciences Europe, Erembodegem, Belgium) in order to remove debris.
Cells were centrifuged and washed twice with PBS, counted and plated in
1103Osteoarthritis and Cartilage Vol. 16, No. 924-well tissue culture plates for chondrocyte culture. Cells were sub-cultured
from a chondrocyte primary culture to obtain a sufﬁcient number of cells and
used between the ﬁrst and second passages to warrant chondrocyte
phenotype.
For NO accumulation studies, enzyme-linked immunosorbent assay
(ELISA), and Western Blot (WB) analysis, cells were seeded in P24 multiwell
plates up to complete adhesion (85e90%conﬂuence) and starved overnight in
serum free conditions (forWBanalysis cells were seeded inP6multiwell plates
as above described). Cells were treated with adiponectin (0.1 and 1 mg/ml) in
the presence of polymixin B (10 mg/ml) in order to neutralize the eventual pres-
ence of endotoxin (which is<0.1 ng/mg of recombinant adiponectin, as stated
by provider’s analysis certiﬁcate). Different speciﬁc pharmacological inhibitors
were added 1 h before stimulation: aminoguanidine (1 mM) for NOS2 activity
blockade, LY294002 (10 mM) for phosphatidylinositol 3-kinase (PI3-K) inhibi-
tion and dexamethasone (10 mM) to inhibit NOS2 de novo synthesis. All treat-
ments were performed at least in three independent experiments.IMMUNOFLUORESCENCE MICROSCOPYCell slide preparation
Cells were seeded on glass microslides and unless otherwise speciﬁed,
all cell lines were ﬁxed in 90% ethanol for 10 min and mounted on Dako
adhesion microslides (DakoCytomation, Carpinteria, CA, USA).
Primary antibodies and procedure
Rabbit anti-adiponectin receptor 1 (AdipoR1) and anti-adiponectin recep-
tor 2 (AdipoR2) (Phoenix Pharmaceuticals, Inc, Belmont, CA, USA) diluted
1:100, for 1 h at room temperature; mouse anti-collagen II (Chemicon,
Temecula, CA, USA) diluted 1:20, overnight at 4C. Collagen II epitope re-
trieval was done by microwave oven in 0.05 M Tris EDTA buffer pH 9
(20 min at 700 W) and proteinase K (40 ml in 2 ml 0.05 M Tris HCl pH
7.5, Dako) 5 min at 37C. In the single immunoﬂuorescence, primary anti-
bodies were incubated as above described. Detection system used in this
case was an anti-rabbit antibody (Ab) conjugated with Alexa 488 (1:200,
for 1 h at room temperature; Molecular Probes, Carlsbad, CA, USA) for Adi-
poR1 and AdipoR2; anti-mouse Ab conjugated with Cyanine 3 (Sigma, St
Louis, MO, USA) 1:100 for 1 h for collagen II. For double immunoﬂuores-
cence the protocol was as follows: (1) epitope retrieval: 20 min microwave
oven in Tris EDTA buffer, pH 9 and proteinase K (5 min at 37C); (2) ﬁrst
primary Ab mouse anti-collagen II 1:20 overnight at RT; (3) anti-mouse Cy-
anine 3 (1:100, 1 h); (4) second primary Ab: AdipoR1 or AdipoR2; (5) and
anti-rabbit conjugated with Alexa 488 (1:200, 1 h). Between steps, slides
were washed twice for 5 min with tris buffered saline (TBS) (Tris 20 mM,
NaCl 137 mM) and after step 5 in distilled water. At the end, slides were
mounted with Immuno-Fluore mounting medium (ICN, Aurora, OH, USA).
The sections were observed and photographed by using a Provis AX70 mi-
croscope (Olympus Corp., Tokyo, Japan).RNA ISOLATION AND RT-PCRRNA was isolated from cell culture by TRIzol LS, according to the manu-
facturer’s instructions (Gibco BRL Life Technologies, Grand Island, NY,
USA) as previously described21. Brieﬂy, total RNA (2e5 mg) was used to per-
form RT-PCR. Complementary DNA (cDNA) was synthesized using 200
units of Moloney murine leukemia virus (MMLV) RT (Gibco BRL) and 6 ml
of deoxynucleotide triphosphate (dNTP) mix (10 mM of each dNTP), 6 ml of
ﬁrst-strand buffer (250 mM Tris HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2;
Gibco BRL), 1.5 ml of 50 mM MgCl2, 0.17 ml of random hexamer solution
(3 mg/ml; Gibco BRL), and 0.25 ml of RNAseOut (recombinant ribonuclease
inhibitor, 40 units/ml; Gibco BRL), in a total volume of 30 ml. Reaction mix-
tures were incubated at 37C for 50 min and at 42C for 15 min. The RTTable
Primer sequences and amplification
Ampliﬁcation conditions Mouse AdipoR1 Mouse AdipoR2 Huma
Annealing temperature ((C) 60 60
Product size 132 72
Number of cycles 40 40
Accession number BC014875 XM_132831 NM_
Forward 470e491 564e586 110
Accession number BC014875 XM_132831 NM_
Reverse 592e602 614e635 115
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.reaction was terminated by heating at 95C for 5 min, and the mixture was
subsequently quick-chilled on ice. Three microliters of the RT reaction mix-
ture was used for PCR ampliﬁcation. The ampliﬁcation conditions were as
follows: 5 ml of PCR buffer (200 mM Tris HCl, pH 8.4, and 500 mM KCl;
Gibco BRL), 1.5 ml of 50 mM MgCl2, 4 ml of dNTP mix, 150 ng of upstream
primer, 150 ng of downstream primer and 1.25 units of Taq DNA polymerase
(Gibco BRL). Ampliﬁcation conditions were as shown in Table I.
Negative controls consisted of omitting the RT reaction mixture for each
sample and amplifying samples of RT reaction mixture without MMLV. To ex-
clude a competitive ampliﬁcation of genomic DNA, RT-PCR was performed
on mouse genomic DNA. The identity of the amplimer was conﬁrmed by per-
forming RT-PCR together with positive controls. PCR products were sepa-
rated on 1.5% agarose gel, stained with ethidium bromide, examined with
ultraviolet light, and visualized with a Typhoon 9410 documentation system
(Amersham Pharmacia Biotech, Little Chalfont, UK).WBHuman cultured chondrocytes and ATDC5 murine chondrogenic cells
were seeded as above described. Cells were stimulated with adiponectin
at different doses (0.1 and 1 mg/ml) and different times (5, 10, 30, 120 min
for 50AMP activated protein kinase (AMPK) activation studies, and 48 h for
NOS type II and PI3-K studies). In some experiments, lipopolysaccharide
(LPS) (500 ng/ml), was used as positive control. After pertinent stimulations,
cells were rapidly washed with ice cold PBS and scraped in Radio Immuno
Precipitation Assay (RIPA) lysis buffer. Lysed cells were centrifuged at
13,000g for 15 min. Lysates from control or stimulated cells were collected
and separated by SDS-PAGE on a 10% polyacrylamide gel. Proteins were
subsequently transferred to a polyvinylidene diﬂuoride transfer membrane
(Hybond TM-P; Amersham International, Little Chalfont, UK).
Blots were incubated with the pertinent primary Ab: (1) anti-NOS2 diluted
1:1000 (Upstate, Lake Placid, NY, USA), (2) AMPK diluted 1:1000, (3) Phos-
pho-AMPK diluted 1:1000 (two and three from Cell Signalling Technology,
Inc, Dambers, MA, USA), (4) anti-b-actin diluted 1:2500 (Sigma, St Louis,
MO, USA) and (5) anti-PI3-K diluted 1:1000 (Upstate, Lake Placid, NY,
USA). Immunoblots were visualized using ECLPlus detection Kit (GE Health-
care, Little Chalfont, UK) using anti-rabbit or anti-mouse horseradish perox-
idase labeled secondary Ab. Images were acquired with an EC3 Imaging
System (UVP, Upland, CA, USA) and densitometred using the ImageMaster
TotalLab tool (GE Healthcare, Little Chalfont, UK).NITRITE ASSAYNitrite accumulation was measured in the culture medium by Griess reac-
tion as previously described20e22.ELISASMMP-2 (DMP200), MMP-3 (MMP300), MMP-9 (MMP900), and TIMP-1
(MTM100) ELISA kits were purchased from R&D Systems Europe, Abing-
don, UK. IL-1b (EMIL1B), IL-6 (EM2IL6), monocyte chemoattractant protein
(MCP)-1 (EMMCP1), TNF-a (EMTNFA), prostaglandin E2 (PGE2)
(EHPGE2) and leukotriene B4 (LTB4) (EHLTB4) were purchased from
Pierce Biotechnology, Rockford, USA. Assays were performed according
to manufacturer’s protocol. Range, sensitivity and inter-assay precisions
were as described by manufacturer’s technical sheets.STATISTICAL ANALYSISAll results are expressed as mean S.E.M. of at least three independent
experiments, each with at least three independent observations. StatisticalI
conditions for PCR reaction
n AdipoR1 Human AdipoR2 Mouse GAPDH Human GAPDH
62 62 Same conditions
of target
Same conditions
of target
71 76 376 376
35 35 Same conditions
of target
Same conditions
of target
015999 NM_024551 M32599 NM_002046
0e1121 1119e1140 531e554 593e616
015999 NM_024551 M32599 NM_002046
1e1170 1177e1194 884e907 946e969
1104 R. Lago et al.: Adiponectin effect on NOS type II in chondrocytesanalysis was performed by analysis of variance (ANOVA) followed by the
StudenteNewmaneKeuls test and Bonferroni or Dunnet multiple comparison
test. A P value less than 0.05 was considered as signiﬁcant.ResultsADIPONECTIN RECEPTORS EXPRESSIONAdipoR1 and AdipoR2 immunofluorescence
As shown in Fig. 1 (left panel) the cytoplasm of murine
ATDC5 cultured cell line and human C28/I2 immortalized
chondrocytes showed intense immunoreactivity with anti-
AdipoR1 (a and e) and anti-AdipoR2 antibodies (b and f).
ATDC5 differentiated chondrocytes showed strong immu-
noreactivity for AdipoR1 and AdipoR2 (c and d). As shown
in Fig. 1 (right panel), immunoreactivity for AdipoR1 was
found in both human normal (a) and osteoarthritic (g) chon-
drocytes. A similar pattern was found for AdipoR2 (d and j).
All analyzed cells were immunoreactive for collagen type II
(b, e, h and k). The possibility that the human cultured cells
were chondrocytes, rather than other cell types, was ruled
out in co-localization studies showing positivity for AdipoR1
and AdipoR2, by their immunoreactivity with Ab against col-
lagen type II (c, f, i and l).
AdipoR1 and AdipoR2 mRNA expression
Data above exposed were further conﬁrmed by studies
aimed to analyze AdipoR1 and AdipoR2 mRNA expressionLeft panel
Adipo R1
C28
Adipo R2
C28
Adipo R1
ATDC5
Adipo R2
ATDC5
Adipo R1
ATDC5 DIF
Adipo R2
ATDC5 DIF
a b
c
e
d
f
hChondr OA
Adipo R1
hChondr OA
Adipo R2
hChondr control
Adipo R1
hChondr control
Adipo R2
Fig. 1. Adiponectin receptors expression in chondrocytes. Left panel: Adip
cell line (a and b, respectively), in differentiated ATDC5 murine cell line (
cytes (e and f, respectively). Right panel: AdipoR1 is expressed in human
cytes from osteoarthritic patients (g). AdipoR2 is expressed in human nor
from osteoarthritic patients (j). All cultured chondrocytes showed positive
marker (b, e, h and k). Co-localization of AdipoRsby RT-PCR. As shown in Fig. 2, murine AdipoR1 and Adi-
poR1 mRNA was found in ATDC5 (AT) cells (Fig. 2, panel
A). Human cultured normal chondrocytes (hC), as well as
human immortalized chondrocyte cell lines TC28a2 (TC),
C28/I2 (C28) and C20A4 (C20) also expressed AdipoR1
and AdipoR2 mRNA (Fig. 2, panel B). Skeletal muscle
(SM) and liver (Liv) were used as positive control for Adi-
poR1 and AdipoR2 expressions, respectively. To note,
functionality of AdipoRs was tested in separate experi-
ments, performed on ATDC5 cells, that showed rapid
phosphorylation of the downstream AMPK in adiponectin-
stimulated cells, as evaluated by WB analysis (Fig. 2,
panel C1) and quantiﬁed by densitometric analysis
(Fig. 2, panel C2).
Adiponectin effect on NOS2 expression and activity
As shown in Fig. 3 (panel A), adiponectin stimulation of
ATDC5 murine cells with different doses (0.1 and 1 mg/ml)
and LPS (500 ng/ml) as positive control, provoked a signiﬁ-
cant increase in nitrite accumulation in the culture superna-
tant. This effect was dependent on the dose and was
evaluated at 24 and 48 h. This result was conﬁrmed also
in terms of NOS2 protein expression.
To conﬁrmwhetherNO formationwas produced viaNOS2,
ATDC5 cells and human chondrocytes were incubated for
48 h with adiponectin in the presence of the NOS2 inhibitor
aminoguanidine (1 mM), added 1 h before adiponectin
administration. Aminoguanidine strongly decreased nitriteRight panel
hCondr OA
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mal cultured chondrocytes (d) and in human cultured chondrocytes
immunoﬂuorescence for collagen type II as chondrocyte speciﬁc
and collagen type II is shown in c, f, i and l.
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Fig. 2. AdipoRs expression and functionality in chondrocytes. Panel A: AdipoR1 and AdipoR2 mRNA expression in ATDC5 (AT) cells deter-
mined by RT-PCR. SM and Liv were used as positive controls. Panel B: AdipoR1 and AdipoR2 mRNA expression in C20A4 (C20), C28/I2
(C28), TC28a2 (TC) and human cultured chondrocytes (hC), determined by RT-PCR. SM and Liv were used as positive controls. Panel C:
WB for phosphorylated AMPK. Phosphorylated AMPK was identiﬁed by phospho-AMPKa Ab Thr172 (Cell Signalling catalog number
2531, 62 kDa) in lysates coming from ATDC5 cells stimulated with adiponectin (1 mg/ml). Phosphorylation levels were evaluated, in time-
dependent experiments, and compared to total AMPK (AMPKa Ab, Cell Signalling catalog number 2532, 62 kDa). Blot is representative of
at least four independent experiments (C1). Densitometric analysis of WB experiments is reported in panel C2. Data are represented as per-
cent S.E.M. over basal AMPK phosphorylation in unstimulated cells.
1105Osteoarthritis and Cartilage Vol. 16, No. 9accumulation in the culture supernatant of ATDC5 cells
(Fig. 3, panel B) and fully inhibited NO accumulation in
human cultured chondrocytes (Fig. 3, panel C). To
note, pre-treatment with dexamethasone (10 mM), a
classic de novo NOS2 inhibitor, also blocked nitrite accu-
mulation in adiponectineATDC5 stimulated cells (Fig. 3,
panel B).
PI3-K inhibition blocks adiponectin-induced NO produc-
tion and NOS2 protein expression.
We also investigated the role played by PI3-K in nitrite
accumulation and NOS2 expression evoked by adiponec-
tin in murine and human chondrocytes by using LY294002
(10 mM). The dose of LY294002 was selected according to
previous published literature20e22. As shown in Fig. 3
(panel B1), PI3-K is phosphorylated after chondrocyte
treatment with recombinant adiponectin. Pre-treatment
with LY294002 speciﬁcally blocked adiponectin-induced
nitrite accumulation in, respectively, murine and human
cultured chondrocytes (Fig. 3, panel B and C). This result
was conﬁrmed also in terms of NOS2 expression since
cell pre-treatment with LY294002 signiﬁcantly decreases
NOS2 protein expression (Fig. 3, panel B2 and C1)and completely inhibited PI3-K phosphorylation (Fig. 3,
panel B1).
Adiponectin effect on cytokines, metalloproteinases
and prostanoids
As shown in Fig. 4, adiponectin was able to signiﬁcantly
increase IL-6, MCP-1, MMP-3 and MMP-9 in the superna-
tant of adiponectin-stimulated ATDC5 cells for 48 h
(Fig. 4, panels AeF, respectively), whereas was unable to
modulate IL-1b, MMP-2 (Fig. 4, panels C and D), TIMP-1,
LTB4, PGE2 and TNF-a [Fig. 5(AeD), respectively]. Inhibi-
tion of PI3-K pathway by LY294002 strongly blunted adipo-
nectin induction of IL-6 and MMP-9 (Fig. 4, panels A and F).
In addition, LY294002 decreased, per se, MMP-2 basal
spontaneous accumulation (Fig. 4, panel D). Intriguingly,
this PI3-K pharmacological blocker was able to partially in-
hibit adiponectin-induced MCP-1 when a minimal dose of
adiponectin was used whereas was unable to counteract
higher adiponectin doses (Fig. 4, panel B). A similar pattern
was observed for MMP-3 (Fig. 4, panel E), where sur-
prisingly, co-stimulation with LY294002 and adiponectin
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1106 R. Lago et al.: Adiponectin effect on NOS type II in chondrocytesseemingly synergized to increase MMP-3 production
by cultured chondrocytes.Discussion
Conversely to the wide range of data in the ﬁeld of endo-
crinology and cardiovascular physiopathology, very little is
known about the role of adipose tissue and adipokines in ar-
ticular degenerative inﬂammatory and/or autoimmune dis-
eases such as RA and OA. Less is known about the
expression and the physiopathological role of adiponectin
in chondrocytes, the unique cartilage cell component.
With regards to joints, only recent ﬁndings demonstrated
that articular adipose tissue and synovial ﬁbroblasts from
patients with joint inﬂammatory diseases are a local source
of adiponectin18. This is also reﬂected by the presence of
adiponectin in synovial ﬂuids from RA and OA patients8.
In addition other authors recently reported that adiponectin
levels in synovial ﬂuids from RA patients are signiﬁcantlyhigher than in OA patients16,25. Therefore, the aim of this
study was to investigate the functional role of adiponectin
in chondrocytes.
Of interest, our data show that murine ATDC5 cells
and both human cultured and immortalized chondro-
cytes express the two isoforms of adiponectin receptors,
which are necessary to transfer the adiponectin-
dependent signals. Therefore, we investigated the effect
of adiponectin in cultured chondrocytes. Up to now,
most of the endocrinological and cardiovascular studies,
aimed to delineate the functional role of adiponectin,
reported a protective rather than a pro-inﬂammatory or
detrimental role of this molecule. One previous report
postulated potential roles of adiponectin in cartilage,
suggesting that joint tissues might be targets for this
adipokine, where it may exert several modulatory effects
including up-regulation of TIMP-2 and down-regulation
of IL-1b-induced MMP-1316. So, these authors suggested
that adiponectin might have a potential protective role in
osteoarthritic joints16.
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1107Osteoarthritis and Cartilage Vol. 16, No. 9By contrast, our study demonstrates, for the ﬁrst time,
that adiponectin might also exert signiﬁcant pro-inﬂamma-
tory effects in chondrocytes by inducing the expression of
NOS2 and also by strongly stimulating IL-6, MMP-3,
MMP-9 and MCP-1 release.
NO, produced in great amounts by the NOS2 inducible
synthase, controls a variety of cartilage functions, including
loss of chondrocyte phenotype, chondrocyte apoptosis, and
extracellular matrix degradation26. In vitro, human articular
cartilage is able to produce large amounts of NO27, which
can be enhanced by pro-inﬂammatory cytokines. In addi-
tion, NO production can be signiﬁcantly increased by the
presence of leptin, as shown in our previous works20e22.
The ability of chondrocytes to respond to adiponectin, by in-
creasing speciﬁcally the expression and activity of NOS2,
appears to be highly selective. Indeed, its induction is
blocked by aminoguanidine, a well known NOS2 activity in-
hibitor, and also by dexamethasone (an inhibitor of NOS2
de novo synthesis). Our data regarding adiponectin-
induced factors production by chondrocytes are partially in
agreement with data published by Chen et al., at least for
those regarding MCP-1 and TIMP-116. In contrast to data
reported by these authors, adiponectin, in our hands, was
able to strongly induce IL-6 and MMP-3. This discrepancy
might be due to the different adiponectin doses used in
our experimental set (0.1 and 1 mg/ml, which are in the
physiological range of adiponectin levels), in comparison
to the dose used by Chen et al. (30 mg/ml). Another possi-
bility might be represented by the different technologies
used in the measurement of these parameters.
The ability to respond to adiponectin is not restricted to
chondrocytes. Indeed, other cell types such as adipocytes,synovial ﬁbroblasts, and normal ﬁbroblasts exhibit the
potential to secrete IL-6 upon stimulation with adiponectin
in vitro18,19. To note, all the above mentioned cells are of
mesenchymal origin. Thus, it is conceivable that the ability
to mount a pro-inﬂammatory response when stimulated by
adiponectin could be a common characteristic of mesen-
chymal-derived cells.
To address the question which molecular mechanism
might mediate the induction of NOS2 and cytokines produc-
tion in response to adiponectin, we examined a key pathway
of intracellular signaling. Actually, previous studies address-
ing intracellular effects of adiponectin in energy substrate
metabolism, as well as in cardiovascular diseases, revealed
that one of the intermediates upon adiponectin binding to its
respective receptors is the PI3-K28,29. To note, PI3-K has
been previously described as a relevant intracellular
signaling molecule involved also in the NOS2 induction in
chondrocytes elicited by several pro-inﬂammatory cytokines
including leptin5. Consistent with this hypothesis, we
demonstrated that PI3-K pharmacological blockade by
LY294002 resulted in a marked reduction of adiponectin-
induced NOS2 expression, as well as in a decrease of adi-
ponectin-induced IL-6 and MMP-9 production. Intriguingly,
LY294002 was able to partially attenuate adiponectin-
induced MCP-1 and MMP-3, suggesting that other alternate
and/or convergent signaling pathways, rather than PI3-K,
are at play. Finally, LY294002 was able to strongly de-
crease basal MMP-2 production in chondrocytes, per se.
Very recently, it has been reported that LY294002 signiﬁ-
cantly reduces adiponectin-induced nuclear factor kappa
B (NFkB) activity in monocytic cells U937 where adiponectin
provoked, among other actions, the induction of MCP-130.
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1108 R. Lago et al.: Adiponectin effect on NOS type II in chondrocytesFinally, recent data by Tang et al., indicated that adiponec-
tin-induced IL-6 production in synoviocytes occurred via p38
and NFkB activation19. To note, the activation of this nuclear
transcription factor is a key element for the triggering of
NOS2 in several cell lineages31.
In conclusion, these data show for the ﬁrst time that adipo-
nectin is a frank modulator of the inﬂammatory response in
chondrocytes. Upon these cells, adiponectin is able to induce
key mediators of cartilage degeneration such as NO, IL-6,
MCP-1 and metalloproteinases such as MMP-3 and MMP-
9, whose induction appears to be modulated by at least
one limited regulating mechanism represented by PI3-K.
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